Related Experiment Video

Updated: Jun 13, 2026

Adaptation of Semiautomated Circulating Tumor Cell (CTC) Assays for Clinical and Preclinical Research Applications
14:14

Adaptation of Semiautomated Circulating Tumor Cell (CTC) Assays for Clinical and Preclinical Research Applications

Published on: February 28, 2014

Selection criteria for c-Met-targeted therapies: emerging evidence for biomarkers

Liliane Goetsch1, Véronique Caussanel

  • 1Centre d'Immunologie Pierre Fabre, Saint Julien en Genevois, France. liliane.goetsch@pierre-fabre.com

Biomarkers in Medicine
|April 14, 2010
PubMed

Insights

Identifying patient subsets for targeted therapies requires robust biomarkers. This review focuses on c-Met receptor alterations in cancer, proposing approaches for selecting effective stratification biomarkers for patient selection in clinical trials.

Area of Science:

  • Oncology
  • Molecular Biology
  • Translational Medicine

Background:

  • Targeted therapies require reliable biomarkers for patient stratification.
  • Identifying responsive patient subsets is crucial for clinical trial success.
  • Examples like trastuzumab (Her2 amplification) highlight biomarker importance, while EGF receptor presents challenges.

Purpose of the Study:

  • To review c-Met receptor alterations in various cancers.
  • To propose strategies for selecting stratification biomarkers for c-Met targeted therapies.
  • To enhance patient selection for early clinical trials.

Main Methods:

  • Literature review of c-Met alterations in cancer.
  • Analysis of existing data on receptor tyrosine kinases and biomarkers.
  • Synthesis of information to propose biomarker selection approaches.

Main Results:

  • c-Met receptor is frequently altered in numerous cancers.
  • Genetic alterations in c-Met are relevant for targeted therapy response.
  • Understanding c-Met biology is key to developing predictive biomarkers.

Conclusions:

  • c-Met alterations represent a significant area for biomarker development in oncology.
  • Effective stratification biomarkers are essential for optimizing c-Met targeted therapies.
  • Further research into c-Met pathways will facilitate personalized cancer treatment.

More Related Videos

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...